RECQL and central nervous system cancer: PARK7 was significantly increased in both GBM and GIV sample groups, relative to controls (Tables S10 and S11) and RECQL was a top-50 DE plasma-EV protein, with high levels distinguishing GIV from GIII gliomas (10.7-fold, adj.